Fight For Lipitor: FDA Calls For Dismissal Of Mylan's Plea On Ranbaxy's AIP

FDA's court filing discloses that the agency and Ranbaxy are in ongoing discussions to resolve the issues described in earlier letter invoking AIP, used when there are significant data integrity issues in drug applications.